Guselkumab Shows Psoriasis Benefit in Darker Skin Tones - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

  • By

  • Andrea Surnit

  • May 14, 2026

  • 3 min

Share

Objective:

To evaluate the efficacy of guselkumab in improving skin clearance and symptoms in patients with moderate to severe plaque psoriasis who self-identify as non-White.

Key Findings:
  • 74% of guselkumab-treated patients achieved IGA 0-1 compared to 0% in the placebo group.
  • 57% of guselkumab patients achieved PASI 90 compared to 4% in the placebo group.
  • 33% of guselkumab patients achieved complete clearance (IGA 0 and PASI 100) versus 0% in placebo.
  • Improvements in disease severity and body surface area were greater with guselkumab, maintained through week 48.
  • Adverse events occurred in 38% of guselkumab patients, primarily infections.
Interpretation:

Guselkumab demonstrated significant efficacy in improving psoriasis symptoms and quality of life in patients with darker skin tones, with sustained responses over time.

Limitations:
  • The trial was not powered for subgroup comparisons across different skin tones.
  • Crossover design limited long-term comparisons with placebo.
  • Sample size was modest.
Conclusion:

Guselkumab is a highly effective and durable treatment for psoriasis in individuals across all skin tones, with no new safety signals identified.

Original Source(s)

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

  • by Andrea Surnit

  • May 14, 2026

Related Content

GLP-1 RAs May Ease Psoriasis, PsA Data Limited

Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.

The Circadian Skin: Chronobiology as a New Frontier in Dermatological Therapy

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis